Not medical advice. A record of published research and our assessments of it. The limits

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

Effects of Degludec/Liraglutide on Time in Range, Markers of Inflammation and Endothelial Dysfunction Compared to Scheme Insulin Basal Bolus, in a Population of Diabetic Inpatients and Possible Correlation With Intra-hospital Mortality Rates
NCT05360537 on ClinicalTrials.gov

Status: CompletedResults none
Why it is watched: non-weight indication: inflammation, mortality
Who it enrolls: age 18 Years to 90 Years; no BMI minimum stated; conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Degludec / Liraglutide Injectable Product; Insulin Glargine
Conditions: Diabetes Mellitus, Type 2
Phase and size: Phase 4 · 100 participants
Dates: Start 2021-04-01
Primary completion 2021-12-01
Sponsor: University of Palermo (Other)
Last checked: Sep 13, 2026

01Endpoints

What the trial will measure

Change of Time in Range % at 7 days, at 1 and 6 months7 days, 1 months and 6 months
Change of hypoglycemic events7 days, 1 months and 6 months
Change from Baseline Reactive Hyperemia Index at 3 and 9 months7 days, 1 months and 6 months

02Eligibility

Who can take part

Inclusion Criteria: * Diabetes mellitus type 2 * Mild-moderate Hyperglycemia (180-400 mg/dl) * Acute events (Pneumonia, Acute cardiac Ischemia, Ictus, IVU) Exclusion Criteria: * Diabetes mellitus type 1 * Diabetic ketoacidosis * Hyperosmolar coma * Severe hypoglycaemia * Acute Pancreatitis * Cancer * use of corticosteroids * pregnancy * Chronic kidney disease (\< 30 ml/min) or hemodialysis

03Change log

Registry changes

No changes recorded since the trial was added.